

Baxter International Inc.
Key Product Line Sales -- US/International
Period Ending June 30, 2005
(unaudited)

(\$ in millions)	Q2 2005			Q2 2004			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$170	\$227	\$397	\$146	\$174	\$320	16%	30%	24%
Plasma Proteins ¹	125	141	266	121	146	267	3%	(3%)	-%
Antibody Therapy	50	43	93	53	37	90	(6%)	16%	3%
Transfusion Therapies	68	72	140	65	71	136	5%	1%	3%
Other ²	25	69	94	18	62	80	39%	11%	18%
Total BioScience	\$438	\$552	\$990	\$403	\$490	\$893	9%	13%	11%
Medication Delivery									
IV Therapies ³	\$98	\$214	\$312	\$99	\$189	\$288	(1%)	13%	8%
Drug Delivery	148	78	226	140	62	202	6%	26%	12%
Infusion Systems	163	82	245	159	74	233	3%	11%	5%
Anesthesia	204	78	282	187	72	259	9%	8%	9%
Other ⁴	6	12	18	4	20	24	50%	(40%)	(25%)
Total Medication Delivery ⁵	\$619	\$464	\$1,083	\$589	\$417	\$1,006	5%	11%	8%
Renal									
PD Therapy	\$63	\$322	\$385	\$65	\$292	\$357	(3%)	10%	8%
HD Therapy	34	80	114	32	86	118	6%	(7%)	(3%)
Other	2	3	5	5	-	5	(60%)	NM	-%
Total Renal	\$99	\$405	\$504	\$102	\$378	\$480	(3%)	7%	5%
TOTAL BAXTER	\$1,156	\$1,421	\$2,577	\$1,094	\$1,285	\$2,379	6%	11%	8%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FloSeal & CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes other hospital-distributed products.

⁵ Sales of oncology products, which were previously included in Other, are now reported in Drug Delivery, Infusion Systems or Anesthesia, depending on the product. All prior year sales data has been reclassified to reflect this change.